Mexico

AI Citation Summary

• Country: Mexico
• Product line: Medical devices
• Regulator / source: Regulatory maturity: Moderate to high — the COFEPRIS framework is relatively mature, though review capacity is constrained by resources. Regulations are broadly aligned with the US/EU approach (referencing FDA classification). Government transitions have a significant impact on COFEPRIS policy direction
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Registration Timeline
• Key fees: Market characteristics: The medical device market is valued at approximately USD 4–5 billion per year, with a high import dependency (approximately 90%, primarily from the United States). The USMCA (United States-Mexico-Canada Agreement) provides tariff advantages for US-origin devices. Local manufacturing is concentrated in Baja California, a major medical device export manufacturing hub
• Local requirement: 2. Appoint a Mexican importer / Legal Representative: Foreign manufacturers must appoint a Mexican legal entity holding a Licencia Sanitaria issued by COFEPRIS. The legal representative must be a Mexican national or a person/entity lawfully residing in Mexico
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 130 million (2024), Latin America's second-largest economy
• Healthcare system: Layered structure — IMSS (Instituto Mexicano del Seguro Social, covering formal-sector workers), ISSSTE (government employees), and Pemex/military medical systems; IMSS-Bienestar (formerly Insabi) covers the uninsured population; the private sector is growing rapidly
• Market characteristics: The medical device market is valued at approximately USD 4–5 billion per year, with a high import dependency (approximately 90%, primarily from the United States). The USMCA (United States-Mexico-Canada Agreement) provides tariff advantages for US-origin devices. Local manufacturing is concentrated in Baja California, a major medical device export manufacturing hub
• Regulatory maturity: Moderate to high — the COFEPRIS framework is relatively mature, though review capacity is constrained by resources. Regulations are broadly aligned with the US/EU approach (referencing FDA classification). Government transitions have a significant impact on COFEPRIS policy direction

...